238 related articles for article (PubMed ID: 6376629)
21. Persistently circulating C3 nephritic factor (C3 NeF)-stabilized alternative pathway C3 convertase (C3 CoF) in serum of an 11-year-old girl with meningococcal septicemia--simultaneous occurrence with free C3 NeF.
Wahn V; Müller W; Rieger C; Rother U
Pediatr Res; 1987 Aug; 22(2):123-9. PubMed ID: 3658535
[TBL] [Abstract][Full Text] [Related]
22. A complement-resistant HeLa cell line (T638) is blocked at the step of C3 deposition.
Santi P; Joiner KA; Hammer CH; Frank MM; Tosi R
J Immunol; 1987 May; 138(10):3385-91. PubMed ID: 2952716
[TBL] [Abstract][Full Text] [Related]
23. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
[TBL] [Abstract][Full Text] [Related]
24. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.
Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M
Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694
[TBL] [Abstract][Full Text] [Related]
25. Steady state relations between control proteins regulating the formation of the alternative pathway C3 convertase.
Reeve J; Woo PM
Immunology; 1982 Aug; 46(4):859-66. PubMed ID: 6921154
[TBL] [Abstract][Full Text] [Related]
26. C3 convertase of the human alternative pathway of complement: modulation of enzyme activity and stability by mouse monoclonal antibodies to Bb.
Fishelson Z; Müller-Eberhard HJ
Eur J Immunol; 1987 Feb; 17(2):303-4. PubMed ID: 3644748
[TBL] [Abstract][Full Text] [Related]
27. Activation of human complement by heat-killed, human kidney cells grown in cell culture.
Baker PJ; Osofsky SG
J Immunol; 1980 Jan; 124(1):81-6. PubMed ID: 6765971
[No Abstract] [Full Text] [Related]
28. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
29. Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein.
Daha MR; van Es LA
J Immunol; 1980 Nov; 125(5):2051-4. PubMed ID: 6903579
[TBL] [Abstract][Full Text] [Related]
30. gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway.
Fischer E; Ouaissi MA; Velge P; Cornette J; Kazatchkine MD
Immunology; 1988 Oct; 65(2):299-303. PubMed ID: 2973433
[TBL] [Abstract][Full Text] [Related]
31. C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1982 Dec; 129(6):2603-7. PubMed ID: 6923908
[TBL] [Abstract][Full Text] [Related]
32. Modulation of the activity of the classical complement pathway C3 convertase by surface-bound C3 or C5.
Strunk RC; Giclas PC
J Immunol; 1980 Feb; 124(2):520-6. PubMed ID: 7356706
[No Abstract] [Full Text] [Related]
33. C3 requirements for formation of alternative pathway C5 convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Aug; 117(2):630-4. PubMed ID: 950465
[TBL] [Abstract][Full Text] [Related]
34. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase.
Moore FD; Austen KF; Fearon DT
J Immunol; 1982 Mar; 128(3):1302-6. PubMed ID: 6915957
[TBL] [Abstract][Full Text] [Related]
35. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2018; 9():612. PubMed ID: 29670616
[TBL] [Abstract][Full Text] [Related]
36. Modulation of classical C3 convertase of complement by tear lactoferrin.
Kijlstra A; Jeurissen SH
Immunology; 1982 Oct; 47(2):263-70. PubMed ID: 6922088
[TBL] [Abstract][Full Text] [Related]
37. Freeze-thaw activation of the complement attack phase: II. Comparison of convertase generated C--56 with C--56 generated by freezing and thawing.
Dessauer A; Rother U; Rother K
Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():83-8. PubMed ID: 6444196
[TBL] [Abstract][Full Text] [Related]
38. [Selective binding in vitro of a modified form of the C3 component of complement to human erythrocytes].
Micouin C; Hudry-Clergeon E; Roussel B; Battail N; Tournoud A; Colomb MG
Ann Immunol (Paris); 1983; 134C(2):237-53. PubMed ID: 6223572
[TBL] [Abstract][Full Text] [Related]
39. The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase.
Isenman DE; Podack ER; Cooper NR
J Immunol; 1980 Jan; 124(1):326-31. PubMed ID: 7350230
[TBL] [Abstract][Full Text] [Related]
40. Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B.
Daha MR; Fearon DT; Austen KF
Immunology; 1976 Nov; 31(5):789-96. PubMed ID: 992711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
